SynthesisFrontiers in public health2025
Non-tuberculous mycobacterial infections in mainland China and Taiwan: a systematic review and meta-analysis of epidemiology, species distribution, and drug resistance (2013-2024).
Synthesis in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Current Perspectives onInternational journal of molecular sciences · 2026Review
- Mycobacterium nanjing sp. nov. Isolated from Cutaneous Infection, China.Emerging infectious diseases · 2026Article
- Fluoroquinolones as the linchpin of tuberculosis therapy: contrasting efficacy and resistance profiles inFrontiers in cellular and infection microbiology · 2026Article
- Host susceptibility spectrum and diagnostic challenges in pediatric nontuberculous mycobacterial disease: a case series of five patients with literature review.Frontiers in pediatrics · 2026Article
- Performance Evaluation of Targeted Nanopore Sequencing in Non-Tuberculous Mycobacteria Identification: A Comparative Study in Shenzhen, China.Infection and drug resistance · 2026Article
- Species Distribution and Antimicrobial Susceptibility Profiles of Non-Tuberculous Mycobacteria in Nanjing, Jiangsu Province, China: A Three-Year Retrospective Study.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Non-tuberculous mycobacteria (NTM) represent an emerging public health threat in China. Despite evidence of rising NTM prevalence and significant regional variation, comprehensive and up-to-date nationwide data on epidemiology, species distribution, and drug resistance patterns have been lacking. This study aimed to systematically evaluate the prevalence, geographical and temporal trends, species composition, and antimicrobial resistance of NTM in mainland China and Taiwan from 2013 to 2024. Methods: Adhering to PRISMA guidelines, this systematic review and meta-analysis (PROSPERO: CRD42024540102) included 43 studies (2013-2024) encompassing 17,959 NTM isolates from 225,733 suspected TB patients. Stata software was used for meta-analysis with a random-effects model; publication bias was assessed via Egger's test and funnel plots. Results: The pooled NTM prevalence among suspected tuberculosis patients was 11.27% (95% CI: 9.89-12.65%), with marked geographic variation: highest in northeast (24.18%) and southeast coastal regions (12.83%), and lowest in southwest (2.30%). Slowly growing mycobacteria accounted for 68.07% of isolates, dominated by Conclusion: NTM prevalence in China has continued to rise over the past decade and now exceeds many global estimates, with pronounced coastal-southern predominance. The persistently high resistance to standard antituberculosis drugs underscores the urgent need for standardized diagnostic protocols, mandatory NTM reporting, enhanced surveillance networks, and region-tailored treatment guidelines. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024540102.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.